Pfizer’s AstraZeneca pursuit knocked by Shire deal collapseThe chances of Pfizer reviving its pursuit of AstraZeneca have been greatly diminished after the collapse of AbbVie’s £32bn acquisition of Shire, according to several people close to the situation.Pfizer, the biggest US drugmaker, would be free under UK Takeover Panel rules to make a new approach for AstraZeneca from next month when a mandatory cooling-off period ends following its failed £69.4bn bid in May.However, such a move has become much less likely after AbbVie, another US drugmaker, backed away from its deal with UK-listed Shire because of a White House clampdown on foreign takeovers that allow American companies to cut their US tax bills, these people said.Pfizer’s thinking could change after the US midterm elections next month if President Barack Obama – who has led the campaign against so-called tax inversions – loses support in Congress.But AbbVie’s U-turn on Shire has highlighted the increased obstacles facing inversion deals. The Chicago-based company said the new rules had “fundamentally changed” the economics of its proposed acquisition.Pfizer and AbbVie are among more than a dozen American companies that have sought deals this year to shift their tax domicile overseas to escape the 35 per cent US corporate tax rate – the highest in the developed world. Pfizer had hoped to cut its average tax rate from 27 per cent to 21 per cent by buying AstraZeneca and moving to the UK. The Treasury clampdown has made it harder for companies to use inversions to shield offshore cash from US taxes.After rejecting Pfizer’s £55-a-share offer in May, AstraZeneca said £58.50 was the minimum level at which it would have considered entering negotiations. Analysts said the Treasury measures had made it tougher for Pfizer to reach such a price.These analysts said that the chances of a Pfizer approach for Actavis, the Dublin-based generic and speciality drugmaker often touted as an alternative potential target for the US company, had also been reduced.If an inversion is ruled out, Ian Read, Pfizer’s chief executive, will be under pressure to come up with other ways to boost performance after a period of sluggish growth and lacklustre drug development.AstraZeneca faced criticism from some shareholders for rebuffing Pfizer. But people familiar with AstraZeneca’s thinking said the AbbVie-Shire collapse reinforced the company’s concern over the political risks involved in inversions.They pointed out the disruption that would have been caused to its business – particularly its research and development pipeline – if it had agreed a deal with Pfizer only for it subsequently to collapse.Shares in AstraZeneca, which peaked at £48.23 after Pfizer’s approach, have fallen back to £41.96. But Pascal Soriot, chief executive, has repeatedly voiced confidence in the company’s standalone prospects with several promising experimental drugs in development.Pfizer and AstraZeneca declined to comment.
Asian Market Update: Rally led by Nikkei225 on GPIF reallocation chatter
***Economic Data*** - (NZ) NEW ZEALAND SEPT PERFORMANCE SERVICES INDEX: 58.0 V 57.7 PRIOR - (NZ) NEW ZEALAND OCT ANZ CONSUMER CONFIDENCE INDEX: 123.4 V 127.7 PRIOR (1-year low) - (KR) SOUTH KOREA SEPT PPI Y/Y: -0.4% (2nd consecutive decline) V -0.2% PRIOR - (UK) UK OCT RIGHTMOVE HOUSE PRICES M/M: 2.6% V 0.9% PRIOR (5-month high); Y/Y: 7.6% V 7.9% PRIOR
***Index Snapshot (as of 02:30 GMT)*** - Nikkei225 +3.3%, S&P/ASX +0.9%, Kospi +1.6%, Shanghai Composite +0.3%, Hang Seng +0.6%, Dec S&P500 +0.5% at 1,889
***Commodities/Fixed Income*** - Dec gold -0.2% at $1,236, Nov crude oil +0.5% at $83.13/brl, Dec copper -0.3% at $2.99/lb - SLV: iShares Silver Trust ETF daily holdings fall to 10,681 tonnes from 10,717 tonnes prior (lowest since Sept 23rd) - (JP) BOJ offers to buy ¥300B in 1-3yr JGB, ¥200B in 3-5yr JGB, ¥400B in 5-10yr JGB as well as ¥400B in CP - (KR) South Korea sells KRW1.8T in 10-yr govt Bonds; avg yield of 2.782%; Bid-to-cover: 3.68x
***Market Focal Points/Key Themes/FX*** - After falling some 5% last week, the Nikkei225 is leading regional bourses to the upside with an over 3% jump. Along with an impressive rebound on Wall St on Friday and weaker JPY, traders are reacting to a Nikkei report speculating the pension fund GPIF will increase its portfolio allocation for domestic stocks to 25% (from current midpoint of 12%) in a move as early as this month. A note from ANZ suggests the report will help reverse the recent strength in JPY, and indeed the USD/JPY pair is up for the 3rd consecutive session with a 50pip rise above ¥107.30. Japan chief cabinet Sec Suga responded to press speculation, stating he does not have any facts regarding plans for GPIF reallocation. Separately, BOJ Gov Kuroda reiterated domestic economy continues to recover as a trend and the central bank will continue its easing policy until 2% inflation is stable, while also adding core CPI would hover just above 1% for some time.
- Over the weekend, situation in Hong Kong continued to deteriorate as clashes between students and police resulted in 70 people injured and dozens arrested. Subsequent reports indicate talks between the two camps will take place on Tuesday, though some 70% of protesters surveyed do not anticipate any compromise from the govt. Meanwhile, chief exec CY Leung put some of the blame for the crisis on "external forces."
- In China, CICC speculated the PBoC may inject another CNY400B into the banking system through Pledged Supplementary Lending facility. This follows reports of a CNY200B injection in 3-month standing liquidity facility (SLF) into the banking system, estimated as the equivalent of a 20bp cut in RRR rate.
- Outside of weaker JPY, other USD majors are generally "risk-on" with higher AUD and NZD against the greenback. AUD/USD was up some 40pips from Friday close above $0.8780, and NZD/USD also rallied about 40pips to session-high of $0.7960. EUR/USD is little changed in a 30pip range around $1.2750.
***Equities*** US markets: - QEP: Announces sale of its midstream business to Tesoro Logistics for $2.5B; Tesoro to raise Q3 dividend by 4% to $0.6425 from $0.615 - IBM: Agrees to acquire chip making unit from Globalfoundries for $1.5B - financial press
Notable movers by sector: - Consumer Discretionary: Guangzhou Automobile Group 2238.HK +3.2% (Guangzhou Auto-Toyota sales target); Daiken Corp 7905.JP -3.2% (lowers FY14/15 guidance) - Materials: Resolute Mining RSG.AU -4.0% (Q1 production results) - Energy: Energy Resources of Australia ERA.AU +2.9% (drilling update); Ausdrill ASL.AU -11.5% (FY15 guidance) - Industrials: Transfield Services TSE.AU +27.0% (receives proposal) - Technology: Moshi Moshi Hotline 4708.JP +8.1% (H1 guidance); NEC Corp 6701.JP +4.9% (press report on H1 results) - Healthcare: Tonghua Golden-Horse Pharmaceutical Industry 000766.CN +3.6% (9M results) - Telecom:Ten Network Holdings TEN.AU +5.9%, Fairfax Media FXJ.AU +1.9% (in discussion on merger)
Companies target the $15tn silver economy
Ford is developing a driving seat that can detect a potential heart attack and bring the car safely to a stop, joining a lengthening list of companies tapping into the world’s growing market of wealthy over-60s. The global spending power of the now elderly "baby boomer" generation – which has more money, lives longer and is more active than their parents – will reach $15tn by 2020, Euromonitor has forecast. Consumption spending among those aged 60 and over rose 50 per cent faster than those under 30 in the past two decades, according to Eurostat. In a six part series, the Financial Times takes an in-depth look at the changes being forced on industries ranging from technology to entertainment as companies wake up to the opportunities provided by the world’s rapidly ageing population. By 2050, the number of those aged more than 65 will outnumber children aged five and under for the first time. Pharma and biotech companies are among those increasing investment to meet rising demand from the elderly, with research and development spending in the global life science industry up 3.1 per cent from last year to $201bn, according to research group Battelle. Some 86 per cent of Americans over the age of 65 have at least one chronic medical condition such as heart disease, diabetes or cancer, and more than half have two or more. Ford’s driver-seat technology joins initiatives from other carmakers such as Toyota to take advantage of a growing market of car buyers over 65 that today generates roughly $140bn in annual sales in the US alone. According to a survey carried out by the Silversurfer website for the FT, almost 60 per cent of those aged over 50 say that technology is still not being adapted to their needs. "We observe mega trends, and we observe what customers want and what they will spend their money on," said Pim van der Jagt, managing director of the Ford Research Center. "100-year-olds driving cars will be not abnormal in the future." "We asked our members ‘What is the one thing you don’t want to give up?," said Jody Holtzman who heads thought leadership at the US-based AARP, a group for the over-50s. "They said ‘It’s the car keys.’ The fact is that the auto industry knows this." Not only are people living longer, they enter what used to be thought of as old age in a physical condition much more akin to that of yesterday’s middle-aged consumers, who are increasingly prepared to go on working and earning money after reaching retirement age. Ford’s seat monitors the driver’s cardiovascular system for irregularities, and works with a camera to monitor head movement and sensors on the steering-wheel to spot a possible heart attack, and engage steering and braking systems. "About 30 per cent of people above 65 have some kind of heart irregularity," said Mr van der Jagt. "If they are still driving, then they will have a real interest in this, that they will have it monitored in the car." Ford is reluctant to say when it might be built into its production cars, but Mr van der Jagt said it would take less than five years to scale up to full production. Toyota is conducting field tests in Japan, which has one of the world’s biggest elderly populations, for various sensors and scanners that trigger warning systems at intersections and traffic lights, targeting older drivers who are keen to stay mobile, but whose perception may be impaired.
Macro